Retatrutide Dosing Guide: Complete Titration Schedule & Efficacy Breakdown
Retatrutide is an investigational once-weekly triple agonist, not an FDA-approved medicine. The Phase 2 obesity study used separate 1, 4, 8 and 12 mg target groups, while the reported Phase 3 TRIUMPH-1 program used 4, 9 and 12 mg targets. This guide keeps those programs, procedures and outcomes separate; see Lilly's current status summary.
Retatrutide Dose Overview
The Phase 2 publication reported assigned target groups rather than a universal 1→2→4→8→12 mg ladder. Initial doses varied by target: 1 mg for the 1 mg group, 2 or 4 mg for the 4 and 8 mg groups, and 2 mg for the 12 mg group. The 2 mg step therefore has no standalone target-group outcome in that trial.
| Assigned target | Initial dose reported | Mean body-weight reduction at 48 weeks | What the result means |
|---|---|---|---|
| 1 mg | 1 mg | 8.7% | Assigned-group mean |
| 4 mg | 2 or 4 mg | 17.1% | Assigned-group mean |
| 8 mg | 2 or 4 mg | 22.8% | Assigned-group mean |
| 12 mg | 2 mg | 24.2% | Assigned-group mean |
Lilly's May 21, 2026 TRIUMPH-1 report describes a different target set and a different time point: 19.0%, 25.9% and 28.3% at 4, 9 and 12 mg after 80 weeks under the efficacy estimand, versus 17.6%, 23.7% and 25.0% under the treatment-regimen estimand. The efficacy estimand estimates outcomes assuming continued study treatment, allowing permitted interruptions or modifications, without prohibited weight-management treatments; the treatment-regimen estimand estimates the average effect regardless of adherence or use of those treatments. These sponsor-reported Phase 3 results do not supersede, directly compare with or predict the Phase 2 group means. See the TRIUMPH-1 results for the dated report.
Reported Titration Procedures: Phase 2 and TRIUMPH-1
Week-by-Week Breakdown
A four-week step sequence was reported for TRIUMPH-1 participants assigned to 4, 9 or 12 mg targets. It is included as study context only. The Phase 2 publication does not establish that same intermediate sequence for every target group.
| Weeks | Reported amount | Assigned target | Context |
|---|---|---|---|
| 1–4 | 2 mg | 4, 9 or 12 mg | Reported initial step |
| 5–8 | 4 mg | 4, 9 or 12 mg | 4 mg target stops here |
| 9–12 | 6 mg | 9 or 12 mg | Higher assigned targets |
| 13–16 | 9 mg | 9 or 12 mg | 9 mg target stops here |
| 17+ | 12 mg | 12 mg only | Reported final step |
Total Timeline to Maintenance
In the reported TRIUMPH-1 procedure, the 4 mg group reached its assigned target in week 5, the 9 mg group in week 13, and the 12 mg group in week 17. Reaching the target ended escalation, not treatment. The Phase 2 groups had different initial doses, so these rows should not be combined into a schedule for people outside the trial.
Alternative Titration Schedules
Alternative Escalation Timing for Tolerability
A slower interval may be discussed in a clinical setting when tolerability is a concern, but the evidence summarized here does not establish a universal six-week retatrutide schedule or a predictable outcome. Useful questions include what the assigned protocol permits, which symptoms require a hold, and when the study team wants reassessment.
Faster Escalation: Not Established in These Trials
The Phase 2 and TRIUMPH-1 descriptions here do not validate a three-week escalation schedule. The published results do not provide step-specific nausea, discontinuation or final-weight-loss percentages for that approach.
Dose Selection: Finding Your Optimal Level
Reaching 12mg Isn't Mandatory
The trials assigned targets; they did not prove that everyone should reach the highest target. A target decision requires the actual study protocol, product status, measured response and clinician or study-team assessment.
Option 1: Discussing the Highest Studied Target
The 12 mg target had the largest reported group mean in each study summary, but that does not make it universally appropriate or establish an individual benefit. Discuss target eligibility, tolerability and monitoring with the responsible clinical team.
Option 2: Discussing an Intermediate Target
The Phase 2 8 mg target had a 22.8% mean reduction at 48 weeks. It is not a universally optimal maintenance amount, and the result cannot be used to choose a dose for a particular person.
Option 3: Discussing Tolerability Limits
The 4 mg Phase 2 target had a 17.1% mean reduction. Six mg appeared as a reported TRIUMPH-1 intermediate step, not a Phase 2 target-group outcome. Questions about holding or reducing belong to the assigned protocol or clinician.
Efficacy by Dose: Detailed Data
Body Weight Loss Percentage at 48 Weeks
The following are Phase 2 group means, not individual predictions. For an illustrative 300-lb baseline, the percentages correspond arithmetically to 26.1, 51.3, 68.4 and 72.6 lb; a person's result cannot be inferred from that multiplication.
| Assigned target | Mean body-weight reduction | 300-lb arithmetic illustration |
|---|---|---|
| 1 mg | 8.7% | 26.1 lb |
| 4 mg | 17.1% | 51.3 lb |
| 8 mg | 22.8% | 68.4 lb |
| 12 mg | 24.2% | 72.6 lb |
The dated Lilly report should be read separately from the Phase 2 table. Its two estimands answer different questions about continued treatment and outcomes regardless of discontinuation; neither is a direct comparison with the Phase 2 means.
Injection Technique & Administration
How to Self-Inject Retatrutide
The trials used once-weekly subcutaneous administration under study procedures. Retatrutide has no FDA-approved consumer label, so this page does not provide a generic self-injection protocol. Participants should use the device, site and handling instructions supplied by their study team or product.
Injection Sites
Site selection, rotation and needle details are product- and protocol-specific. Ask the responsible clinician for a demonstration and for instructions that match the actual device; do not treat a general injection-site list as a retatrutide label.
Step-by-Step Injection Instructions
- Confirm the assigned amount, product identity and preparation instructions with the study team.
- Inspect the actual product as its label or study protocol directs; do not infer suitability from appearance alone.
- Use only the supplied device and administration steps, then record the event as the study team requests.
Storage Instructions
Storage time, temperature, light protection and discard rules depend on the actual product and formulation. There is no generic 28- or 56-day retatrutide rule here. A bacteriostatic-water label describes that product's own compatibility and handling, not a retatrutide preparation or storage schedule.
Compounded Retatrutide: Dosing Considerations
The FDA states that retatrutide cannot be compounded under federal law; see its drug-alert statement. That legal status is separate from the promising trial findings and does not make an outside vial equivalent to a trial product. If an outside product is presented to you, its identity, concentration, sterility, vehicle, labeling and instructions still require verification.
Dosing from Compounded Sources
Ask the responsible clinical or study team to identify the actual concentration, final volume, route, device, storage limits and discard date. Do not transfer a dose target from a research paper to an unverified vial.
Product-Specific Reconstitution Instructions
There is no universal bacteriostatic-water recipe in this guide. A DailyMed product label can document a product's vehicle, compatibility and preparation requirements, but it does not authorize those instructions for retatrutide. Use the actual product documentation and qualified clinical guidance.
Dose Adjustments: When and Why
Reducing Dose for Tolerability
The Phase 2 publication described gastrointestinal events as generally mild or moderate and dose-related, with some difference by starting dose. It does not supply a universal reduction, hold or restart algorithm for individual use. Report symptoms promptly and ask what the assigned protocol permits.
Increasing Dose for Additional Weight Loss
A higher target is not automatically the right response to a plateau or a desired outcome. The responsible clinical team must weigh the study assignment, observed response, tolerability and monitoring; this guide does not select an amount or interval.
When Weight Loss Plateaus
A plateau is an observation, not proof that a dose should increase. Review the measurements, adherence, concurrent care, symptoms and study protocol with the responsible clinician before making any change.
First Steps
- Confirm what target and time point the study or clinician actually assigned.
- Check concentration, device, administration records and product storage against the supplied instructions.
- Discuss symptoms, other medicines, nutrition, activity and relevant medical conditions with the clinical team.
If Plateau Persists
Ask whether the study has a prespecified response assessment or stopping rule. A group mean cannot establish an individual endpoint, and an online table cannot justify escalation, switching or discontinuation.
Maintaining Weight Loss After Retatrutide
What Happens When You Stop?
The cited withdrawal studies concern other medicines: the STEP 1 extension describes semaglutide 2.4 mg after treatment withdrawal, and SURMOUNT-4 describes tirzepatide withdrawal; both report weight regain after withdrawal. The current TRIUMPH-6 listing describes an 80-week lead-in followed by a randomized maintenance phase; it reports no completed maintenance results. These sources do not establish how retatrutide behaves after withdrawal.
Strategies for Weight Maintenance
Maintenance planning depends on the medicine, indication, formulation and clinical history. Discuss continued care, follow-up measurements and non-drug support with the treating team; do not assume an unapproved retatrutide maintenance or intermittent schedule.
Dose Considerations for Specific Populations
Patients with Diabetes
Diabetes medicines and glucose monitoring require individualized coordination. This page does not prescribe an insulin or glucose-lowering adjustment for retatrutide.
Patients with Kidney Disease
The summarized trials do not establish a retatrutide renal-impairment dosing rule. Bring kidney function, medicines and the actual study eligibility criteria to the responsible clinician.
Patients with Liver Disease
The summarized trials do not establish a retatrutide hepatic-impairment dosing rule. Ask the study team or clinician how the protocol addresses liver disease rather than inferring an adjustment.
Frequently Asked Dosing Questions
Can you double up after a missed injection? The appropriate response is protocol- and product-specific; no catch-up rule is established here. Does escalation need to be continuous? No universal rule is established here. Is there an upper limit? Twelve mg is the highest target summarized, not an approved prescription.
Comparison to Tirzepatide Dosing
Tirzepatide and retatrutide are different molecules with different receptor targets, indications, labels and evidence. The Zepbound HCP dosing page describes a 15 mg weekly maximum for that product; 15 mg is not a retatrutide conversion, and cross-trial percentages are not a head-to-head result. See our tirzepatide dosing guide for its own product context.
Conclusion
The useful distinction is simple: Phase 2 reported separate 1, 4, 8 and 12 mg target groups with varying initial doses; TRIUMPH-1 reported 4, 9 and 12 mg targets and a four-week procedure for those assignments. Neither creates a universal personal schedule. For the dated Phase 3 report, see the TRIUMPH-1 results.
For related context, read our side effects guide, compare the product-specific tirzepatide dosing information, and review the dosage calculator as arithmetic support rather than a treatment selector.
Frequently Asked Questions
The Phase 2 obesity study assigned separate 1, 4, 8 and 12 mg target groups. Initial doses were 1 mg for the 1 mg target, 2 or 4 mg for the 4 and 8 mg targets, and 2 mg for the 12 mg target. Those group assignments do not establish one starting-dose rule for people outside the study, and retatrutide remains investigational.
The studies summarized here included a 12 mg target, the highest target in the Phase 2 and TRIUMPH-1 obesity programs. That is a trial target, not an FDA-approved prescribing dose or a recommendation to use it. The current Lilly status summary describes retatrutide as investigational.
The Phase 2 and TRIUMPH-1 obesity programs studied once-weekly subcutaneous administration. This describes those trial procedures; it does not create instructions for an unapproved product. Trial participants should follow the assigned study team and product-specific instructions, and daily use has not been established here.
There is no universal Phase 2 timeline to reach 12 mg. The reported TRIUMPH-1 steps were 2, 4, 6, 9 and 12 mg: the 12 mg group reached its assigned target at week 17 after four four-week steps. The 4 mg group reached its target at week 5 and the 9 mg group at week 13, then remained at those targets rather than continuing upward. Those study steps are not a personal escalation schedule.
No. Lower target groups also had mean weight reductions: Phase 2 reported 8.7%, 17.1%, 22.8% and 24.2% for the 1, 4, 8 and 12 mg target groups. TRIUMPH-1 reported a different 4, 9 and 12 mg target set over 80 weeks. These are group results, not a dose-selection rule or an individual forecast.
A study protocol may specify when a participant can hold, reduce or stop an assigned amount, but these pages do not establish a general hold interval. Questions about tolerability, symptoms or a missed study dose belong with the study team or prescribing clinician; do not infer a new schedule from a table here.
The appropriate response depends on the assigned study protocol or actual product instructions. The published sources here do not state a two-day window, restart plan or double-dose rule. Contact the study team or clinician for the specific instruction rather than creating a catch-up schedule.
No daily retatrutide procedure is established by the once-weekly obesity trials summarized here. A different frequency cannot be inferred from those studies or used to construct a compounded regimen.